|
Status |
Public on Jan 23, 2012 |
Title |
80_pT3 |
Sample type |
RNA |
|
|
Source name |
Bladder Cancer
|
Organism |
Homo sapiens |
Characteristics |
gender: male preopclinstage: T2 age at rc: 80.46 survival.months: 17.60986 rc_stage: pT3 rc_histology: TCC plnd result: Nx rc grade: High nomogram score: 38.72907066 distant mets: 0 local recurrence: 1 urothelial recurrence: 0 metastasis: 1 last known status: DOD prerc_chemo: No post rc_chemo: No smoking: Former smokingpack-years: 90 recurrence free survival months (distant and local): 16.26283 recurrence/dod: Yes cluster: 1
|
Treatment protocol |
Frozen bladder tissues were examined by a genitourinary pathologist to identify tumor content, which was microdissected. Ten 50-um sections were cut, with confirmation of tumor content by pathologic review.
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA was isolated with Trizol (Invitrogen) and RNA was cleaned with Rneasy mini kits (Qiagen) according to manufacturer protocols
|
Label |
biotin
|
Label protocol |
Expression profiling was performed in the MSKCC Genomics Core Facility. In brief, 5-10 ug of RNA was transcribed utilizing a T7-oligo dT primer and converted to cDNA (Invitrogen cDNA synthesis kit). Biotinylated aRNA was produced from the cDNA using an in vitro transcription kit (Enzo Diagnostics).
|
|
|
Hybridization protocol |
Following quality assessment using an Agilent Bioanalyzer, the aRNA was fragmented and hybridized onto Affymetrix U133 Plus 2.0 arrays
|
Scan protocol |
Standard Affymetrix protocol.
|
Data processing |
Expression estimates were obtained with GCRMA from Bioconductor with default parameters.
|
|
|
Submission date |
Aug 26, 2011 |
Last update date |
Apr 30, 2012 |
Contact name |
Markus Riester |
E-mail(s) |
[email protected]
|
Organization name |
Dana-Farber Cancer Institute
|
Department |
Biostatistics & Computational Biology
|
Lab |
Michor
|
Street address |
3 Blackfan Circle
|
City |
Boston |
State/province |
MA |
ZIP/Postal code |
02115 |
Country |
USA |
|
|
Platform ID |
GPL570 |
Series (1) |
GSE31684 |
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer |
|